23 4923 paper

Pharmacological Reports Copyright 2012 2012, 64, 205–211 by Institute of Pharmacology Polish Academy of Sciences Influence of the phosphodiesterase type 5inhibitor, sildenafil, on antidepressant-likeactivity of magnesium in the forced swim testin mice Katarzyna Soca³a1, Dorota Nieoczym1, Ewa Poleszak2, Piotr WlaŸ1 1Department of Animal Physiology, Institute of Biology and Biochemistry, Maria Curie-Sk³odowska University,Akademicka 19,PL 20-033 Lublin, Poland 2Chair and Department of Applied Pharmacy, Medical University of Lublin, ChodŸki 1, PL 20-093 Lublin, Poland Correspondence: Piotr WlaŸ, e-mail: [email protected]
Abstract:
Magnesium, which acts as an antagonist of N-methyl-D-aspartate (NMDA) subtype of glutamate receptors, exerts antidepressant-
like activity in animal models of depression. The present study was undertaken to elucidate the influence of sildenafil, a phosphodi-
esterase type 5 inhibitor, on the anti-immobility action of magnesium in the forced swim test in mice. Swim sessions were conducted
by placing mice in glass cylinders filled with water for 6 min and the duration of the behavioral immobility during the last 4 min of
the test was evaluated. Locomotor activity was measured with photoresistor actimeters. Serum and brain magnesium levels were as-
sayed spectrophotometrically. Magnesium at a dose of 30 mg/kg, ip significantly decreased the immobility time while sildenafil (5,
10 and 20 mg/kg, ip) in a dose-dependent manner reduced the antidepressant-like activity of magnesium. The co-administration of
magnesium with sildenafil at the highest dose entirely abolished the antidepressant-like effect of magnesium and caused a statisti-
cally significant increase in immobility duration as compared to the control group. Combination of magnesium with sildenafil re-
sulted in a potent reduction (80%) of locomotor activity and pharmacokinetic studies showed a significant increase of magnesium
concentration in serum (as compared to magnesium treatment alone) without changes within brain tissue in mice treated with mag-
nesium and sildenafil. When given alone, sildenafil caused a significant increase in magnesium levels in both serum and brain. Our
results indicate that a simultaneous treatment with magnesium and sildenafil results in hypermagnesemia in laboratory animals.
However, the mechanism underlying this effect remains elusive.
Key words:
phosphodiesterase 5, sildenafil, magnesium, depression, erectile dysfunction, antidepressant, forced swim test, mice
PDE5) cell signaling pathway [6]. During sexual Sildenafil, an active compound of Viagra, is the first- stimulation, corpus cavernosum nerves and endothe- line oral treatment for erectile dysfunction of multiple lial cells release NO, which via guanylate cyclase ac- etiologies. The mechanism of action of sildenafil in- tivation promotes cyclic guanosine 3´,5´-monopho- volves the nitric oxide/cyclic guanosine 3´,5´-mono- sphate (cGMP) production. Cyclic GMP, in turn, al- Pharmacological Reports, 2012, 64, 205–211 lows corporal smooth muscle cells relaxation and zures [2, 14]. Magnesium deficiency is quite com- leads to an erection. The intracellular level of cGMP mon. In general population, hypomagnesemia is is regulated by PDE5 – an enzyme which hydrolyzes estimated at 6.9% but it varies greatly depending on cyclic nucleotides. Sildenafil works as a selective in- patients' general condition [14]. Numerous magne- hibitor of PDE5. By inhibiting cGMP degradation, it sium dietary supplements are available on the market improves the relaxation of smooth muscles in the cor- and magnesium supplementation is an important issue pus cavernosum and thus resulting in erection [16, in contemporary medicine. Moreover, it is one of the 44]. Sildenafil exerts various effects on the central new emerging approaches in the treatment of depres- nervous system. The recent data show that it pos- sesses neuroprotective properties, enhances neuro- Since both magnesium and sildenafil may alter glu- genesis and improves memory [48].
tamatergic neurotransmission and magnesium supple- The NO/cGMP pathway has also been implicated mentation is of high probability in men taking silde- in the neurobiology of depression. A number of ex- nafil, the aim of the present study was to investigate periments indicate that inhibitors of this pathway ex- the effect of sildenafil on the antidepressant-like ac- hibit antidepressant effects and enhance the efficacy tivity of magnesium in the forced swim test in mice.
of serotonin reuptake inhibitors [17, 18, 20]. Nitric In order to evaluate the potential pharmacokinetic in- oxide plays an extremely important role in the central teractions between sildenafil and magnesium, total nervous system where it acts as a neuronal messenger.
brain and serum concentrations of magnesium were It is involved in neurotransmission, synaptic plastic- ity, perception of pain and learning [12]. The NO/cGMP pathway affects i.a., excitatory neurotransmis-sion mediated through the N-methyl-D-aspartate(NMDA) subtype of glutamate receptors [42]. Inter- Materials and Methods
actions between NO/cGMP pathway and glutamater-gic neurotransmission are bidirectional. On the onehand, stimulation of NMDA receptor results in Ca2+ influx which leads to NO synthase activation and NOproduction. On the other hand, NO and cGMP modu- The experiments were carried out on male Albino late NMDA receptor activity and may regulate release Swiss mice weighing 25–30 g, purchased from a li- of glutamate by negative feedback mechanisms [18, 29, 42]. There is an increasing evidence for the in- S³aboszów, Poland). The animals were housed in volvement of NMDA-mediated neurotransmission in groups of up to 10 mice in polycarbonate cages under pathophysiology of depression and antidepressant- standard laboratory conditions (temperature main- like activity of NMDA receptor antagonists in animal tained at 23–25°C, humidity 50–60% and 12 h studies [19, 32, 33, 45]. Magnesium, which blocks the light/dark cycle, lights on at 06:00 h) with free access NMDA receptor channel in a voltage-dependent fash- to food pellets (Murigran, Agropol S.J., Motycz, Po- ion, also exhibits antidepressant activity in animal land) and tap water. All experiments were performed studies and clinical trials [7, 38, 40]. It is also active following at least 7 days of acclimatization. The ex- in an animal model of mania [1]. This second most perimental protocols were approved by the Ethical abundant intracellular cation plays a fundamental role Committee of the Medical University in Lublin in innumerable regulatory processes. It participates in (license number 69/2009) and all procedures were in over 325 different enzymatic reactions such as hy- accordance with the European Communities Council drolysis of high-energy phosphate groups or nucleic Directive of 24 November 1986 (86/609/EEC).
acid and protein synthesis. It regulates conductivity ofion channels and is involved in hormone receptor binding, muscle contraction and neurotransmitters re-lease [11, 13]. Therefore, magnesium depletion brings Magnesium hydroaspartate (Farmapol, Poznañ, Poland) about dramatic clinical implications ranging from hy- and sildenafil citrate (Polpharma, Starogard Gdañski, pertension, arrhythmias and neuromuscular hyperex- Poland) were dissolved in saline and administered citability to acute myocardial infarction or even sei- intraperitoneally (ip) at a volume of 10 ml/kg, 30 min Pharmacological Reports, 2012, 64, 205–211 Sildenafil and antidepressant-like activity of magnesium
Katarzyna Soca³a et al.
before the respective test. The dosage of magnesium able reagent (Liquick Cor-Mg, Cormay, Lublin, Po- refers to pure magnesium ions. Control animals re- land) and reaction mixture absorbance was measured ceived an ip injection of saline. The doses and pre- at 520 nm employing a spectrophotometer (Hitachi treatment schedules were selected on the basis of U-3010, Tokyo, Japan). The magnesium concentra- those reported in the literature and previous experi- tions were expressed in mg/100 ml for serum and µg/g ments from our laboratory [29–31, 35–38].
of brain tissue.
Forced swim test
The test was conducted according to the method de- All results are presented as the means ± standard error scribed by Porsolt et al. [41]. Mice were placed indi- of the mean (SEM) and evaluated by using one-way vidually in glass cylinders (height 25 cm, diameter analysis of variance (ANOVA) followed by Student- 10 cm). The cylinders contained 10 cm of water main- Newman-Keuls post-hoc test for multiple comparison tained at 23–25°C. Animals were allowed to swim for or by unpaired Student's t-test, where appropriate. A p 6 min. Total duration of immobility was recorded dur- value less than or equal to 0.05 was considered to be ing the last 4 min of the test. The duration of immobil- ity was defined as the time when the mouse remainedfloating passively, made no attempts to escape andshowed only slow movements to keep its head abovethe water.
Forced swim test
Locomotor activity of mice was determined by using The effect of magnesium, alone and in combination actimeters (30 cm diameter, 12 cm high, MultiServ, with sildenafil, on immobility time in the forced swim Lublin, Poland) equipped with two perpendicular in- test in mice is shown in Figure 1 (one-way ANOVA: frared light beams located 1.5 cm above the floor.
F (4, 51) = 35.080; p < 0.001). Magnesium at a dose Mice were placed individually in an actimeter for of 30 mg/kg significantly decreased immobility time 5 min. After acclimatization, locomotor activity was from 193.80 ± 4.38 s in the control group to 132.00 recorded as the number of interruptions of light beams ± 5.69 s (p < 0.001). Sildenafil in a dose-dependent for the next 5 min.
Determination of serum and brain magnesium
concentration
After drug pretreatment, mice were sacrificed by de-capitation and the trunk blood was collected in poly-ethylene tubes. Serum was isolated 1 h after blood co-agulation by centrifugation at 5,000 × g for 10 min at4°C and frozen at –30°C. The brains were rapidly re-moved after decapitation, washed in saline and ho-mogenized (PRP 200, PRO Scientific Inc., Connecti-cut, USA) in 0.1 M phosphate buffered saline (pH7.4) at 26,000 rpm for 3 min at 4°C. The homogenateswere centrifuged at 21,000 × g for 30 min at 4°C andthe supernatant was frozen at –30°C.
Fig. 1. The effect of sildenafil on the antidepressant-like activity of
Total magnesium concentration in serum and brain magnesium in the forced swim test in mice. Magnesium and sildenafilwere administered ip 30 min before the test. Each experimental homogenates was determined by using xylidyl blue group consisted of 10–12 animals. Data are presented as the means method. Ten microliters of thawed serum or brain su- ± SEM. ** p < 0.01, *** p < 0.001 vs. saline-treated group; # p < 0.05, ### p < 0.001 vs. magnesium-treated group (one-way ANOVA with pernatant was mixed with 1 ml of commercially avail- Student-Newman-Keuls post-hoc test) Pharmacological Reports, 2012, 64, 205–211 manner reduced the antidepressant-like activity of mice is shown in Table 1 (one-way ANOVA: F (5, 53) magnesium. The combination of magnesium with = 7.710; p < 0.001). Sildenafil, at any dose tested, as sildenafil at the highest dose of 20 mg/kg entirely well as magnesium administered alone did not affect abolished the antidepressant-like effect of magnesium locomotor activity in mice. The combined administra- and caused a statistically significant increase in total tion of magnesium with sildenafil at the highest dose duration of immobility as compared to saline-treated of 20 mg/kg significantly reduced the activity counts group (p = 0.006).
(p < 0.001 vs. the control group and magnesium-treated group).
Effect of sildenafil on serum and brain
The effect of sildenafil and combined administration of sildenafil and magnesium on locomotor activity in The effects of combined administration of magnesiumand sildenafil on serum (one-way ANOVA: F (2, 30) Tab. 1. Effect of sildenafil and magnesium administered separately
= 118.92; p < 0.001) and brain (one-way ANOVA: or jointly on spontaneous locomotor activity in mice F (2, 30) = 4.169; p = 0.025) magnesium concentra-tions in mice are shown in Table 2. The administration Activity counts/5 min of magnesium at a dose of 30 mg/kg significantly in- creased the concentration of magnesium in serum Sildenafil (5 mg/kg) + saline (p < 0.001) as well as in the brain (p < 0.05) as com-pared to saline-treated group. Co-administration of Sildenafil (10 mg/kg) + saline magnesium with sildenafil (20 mg/kg) caused an Sildenafil (20 mg/kg) + saline additional increase in serum magnesium levels with Magnesium (30 mg/kg) + saline no effect on magnesium concentration within the Magnesium (30 mg/kg) + sildenafil (20 mg/kg) brain (p < 0.001 and p > 0.05 as compared to magne-sium-treated group, respectively).
Magnesium and sildenafil were administered ip 30 min before thetest. Each experimental group consisted of 9–10 animals. Data are The influence of sildenafil administered alone on presented as the means ± SEM. a p < 0.001 vs. saline-treated group; serum (t-test p < 0.001) and brain (t-test p < 0.001) b p < 0.001 vs. magnesium-treated group (one-way ANOVA withStudent-Newman-Keuls post-hoc test) magnesium level is shown in Table 2. Sildenafilcaused a statistically significant increase in magne-sium concentrations in both serum and brain.
Tab. 2. Effect of magnesium and sildenafil administered separately
or jointly on serum and brain magnesium concentrations in mice
Magnesium concentration In recent years, there has been an increased interest in A. Saline + saline
the involvement of magnesium in the pathophysiology Magnesium (30 mg/kg) + saline and treatment of depression. Magnesium deficiency isbelieved to contribute to mood disorders in spite of the Magnesium (30 mg/kg) + sildenafil (20 mg/kg) fact that blood tests of depressed patients provide fre-quently contradictory results. Serum/plasma levels of B. Saline
magnesium ions in depressives may be elevated, de- Sildenafil (20 mg/kg) creased or may remain unchanged [10, 11, 24]. Nu-merous studies indicate that magnesium possesses po- Magnesium and sildenafil were administered ip 30 min before de- tent antidepressant-like properties in the forced swim capitation. Each experimental group consisted of 9–12 animals. Data
are presented as the means ± SEM. A: a p < 0.05, b p < 0.001 vs.
test in rodents and anxiolytic-like activity in the ele- saline-treated group; c p < 0.001 vs. magnesium-treated group vated plus maze test in mice. In addition, the anti- (one-way ANOVA with Student-Newman-Keuls post-hoc test).
B: a p < 0.01, b p < 0.001 vs. saline-treated group (Student's t-test)
immobility action of imipramine, citalopram and tia- Pharmacological Reports, 2012, 64, 205–211 Sildenafil and antidepressant-like activity of magnesium
Katarzyna Soca³a et al.
neptine as well as of NMDA receptor antagonists and Magnesium also activates the activity of guanylate glycineB receptor ligands is enhanced by joint admini- cyclase which promotes cGMP formation [34]. Per- stration of magnesium [7, 36, 37, 40]. Apart from data haps the influence of sildenafil and magnesium, ad- obtained in animal studies, magnesium supplementa- ministered alone, on the GABAergic neurotransmis- tion was reported to be effective in the treatment of sion was too weak to impair locomotor activity in major depressive disorder [10], rapid cycling bipolar mice and only when administered jointly they cause affective disorder [5] and mania [21]. The antidepres- noticeable behavioral response. Data from pharma- sant- and anxiolytic-like effects of magnesium are cokinetic studies revealed, nevertheless, that a distinct most likely related to its antagonist properties to the mechanism could be responsible for the reduction of spontaneous locomotor activity in mice after com- The present study demonstrates that the anti- bined treatment with sildenafil and magnesium. Co- immobility action of magnesium in the forced swim administration of these two substances resulted in test in mice was reduced by sildenafil in a dose- a significant increase in magnesium serum level (by dependent manner. Interestingly, sildenafil, at the 78%), as compared with magnesium treatment alone, highest dose used, not only entirely abolished the without changes within brain tissue. Magnesium magnesium-induced antidepressant effect but also overload occurs rarely, mainly because of excessive prolonged the duration of immobility as compared to intake of magnesium or failure of its excretion. Hy- the control group. These results could imply that com- permagnesemia is manifested by hypotension, brady- bined administration of magnesium and sildenafil cardia, hyporeflexia, neuromuscular hypoexcitability leads to depressogenic effects. As the combination of and sedation [9, 46, 47]. Clinical symptoms of mag- magnesium with sildenafil resulted in a potent reduc- nesium overload may mimic central anesthetic effect.
tion (80%) of the locomotor activity, changes in the But in fact, they are due to the peripheral action of general motor function may have interfered with data magnesium [9]. The brain magnesium concentration obtained in the forced swim test.
is tightly regulated and the blood-brain barrier pro- Locomotion and exploratory behavior are regulated tects against acute changes in the magnesium concen- and mediated by various types of neurotransmitter tration. An acute increase in plasma magnesium con- systems, in particular mesolimbic dopaminergic path- centration is usually not associated with an increase in ways [3, 8, 25, 27]. Sildenafil, which acts through the brain intracellular magnesium concentration [11, 15, NO/cGMP/PDE5 pathway, may affect both excitatory 40]. In most animals, serum magnesium level reaches and inhibitory neurotransmission [42]. Likewise, 1.8–2.7 mg/100 ml and sedation becomes evident at magnesium is involved in signal transmission within serum magnesium level of 4–5 mg/100 ml [28]. It the central nervous system. It acts as non-competitive seems that sildenafil administered with magnesium antagonist of NMDA receptors [39], modulates the leads to hypermagnesemia, as in the present study turnover of different neurotransmitters such as amino sildenafil elevated serum magnesium levels up to acids, neuropeptides, cytokines and nitric oxide [11] 6.5 mg/100 ml. Thus, sildenafil might have enhanced and participates in binding of monoamines to their re- magnesium absorption from the peritoneal cavity ceptors [4]. A common site of action for sildenafil and and/or it could have impaired magnesium renal excre- magnesium may be the GABAA receptor. Increased tion. To establish the mechanism accountable for this GABAergic transmission causes sedation and may effect, in a separate experiment we assayed serum and lead to the reduction of locomotor activity [26].
brain magnesium levels after single administration of Huang et al. [22] showed that increased cGMP con- sildenafil without magnesium pre-treatment. The in- centration evoked by sildenafil treatment enhances creased serum magnesium concentration (by 13%) the release of GABA, while Poleszak [35] suggests after sildenafil treatment implies that hypermagne- that anxiolytic-like effects of magnesium are related semia, observed in former experiment, was rather due to its ability to activate GABAA-gated chloride chan- to the malfunctioning of magnesium transport in kid- nels. In addition, synergistic interaction of magne- neys than the excessive magnesium intake from the sium with benzodiazepines (diazepam and chlordi- peritoneal cavity.
azepoxide) in the elevated plus maze test in mice ar- Mammalian magnesium transport across biological gue for the involvement of benzodiazepine/GABAA membranes is mediated by two main systems: Na+- system in the anxiolytic activity of magnesium [35].
dependent and Na+-independent pathways. Although in- Pharmacological Reports, 2012, 64, 205–211 tracellular magnesium level is precisely regulated, the exact mechanism is not fully understood [43] and lit-tle is known about the involvement of the NO/cGMP 1. Barbosa FJ, Hesse B, de Almeida RB, Baretta IP, pathway in magnesium transport pathways. It is also Boerngen-Lacerda R, Andreatini R: Magnesium sulfate claimed that the peripheral and central magnesium and sodium valproate block methylphenidate-induced level may be regulated by different mechanisms [4].
hyperlocomotion, an animal model of mania. Pharmacol The reabsorption of magnesium predominantly occurs Rep, 2011, 63, 64–70.
2. Bastani B, Pandurangan G: Intraperitoneal route of mag- in the loop of Henle and the distal tubule [2] and ele- nesium sulphate supplementation in a patient with severe ments of the NO/cGMP may regulate renal functions renal magnesium wasting. Nephrol Dial Transplant, because NO as well as cGMP modulate many plasma 2001, 16, 2086–2089.
membrane transporters [23]. Ikari and co-workers 3. Cazalets J: Development ot the neural correlates of loco- [23] showed that NO and cGMP up-regulate the motion in rats. In: Handbook of brain and behaviour in hu-man development. Eds. Kalverboer A, Gramsbergen A, Na+-dependent magnesium transport in renal epithe- Kluwer Academic Publishing, Dordrecht, 2001, 447–467.
lial cells and it was suggested that under pathological 4. Chollet D, Franken P, Raffin Y, Malafosse A, Widmer J, conditions, the increase in magnesium gradient with Tafti M: Blood and brain magnesium in inbred mice and a concomitant increase in NO and cGMP levels acti- their correlation with sleep quality. Am J Physiol Regul vates magnesium transport system across the plasma Integr Comp Physiol, 2000, 279, R2173–R2178.
5. Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (Magnesio- Unexpectedly, in our study, sildenafil, when ad- card) as a mood stabilizer for rapid cycling bipolar affec- ministered alone, caused a 20% increase in magne- tive disorder patients. Prog Neuropsychopharmacol Biol sium level within the brain, which points at a redistri- Psychiatry, 1990, 14, 171–180.
bution of magnesium from blood to the brain and 6. Corbin JD, Francis SH: Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem, 1999, 274, 13729–13732.
a failure of homeostatic regulations of magnesium 7. Decollogne S, Tomas A, Lecerf C, Adamowicz E, concentration within the brain tissue. Because no Seman M: NMDA receptor complex blockade by oral changes in brain magnesium levels after joint admini- administration of magnesium: comparison with MK-801.
stration of magnesium and sildenafil were noticed, it Pharmacol Biochem Behav, 1997, 58, 261–268.
may be speculated that distinct mechanisms may be 8. Del Arco A, Segovia G, Mora F: Blockade of NMDA re- ceptors in the prefrontal cortex increases dopamine and accountable for regulation of the brain magnesium acetylcholine release in the nucleus accumbens and motor concentration under physiological and abnormal con- activity. Psychopharmacology (Berl), 2008, 201, 325–338.
ditions such as magnesium overload. However, the 9. Durlach J, Durlach V, Bac P, Bara M, Guiet-Bara A: Mag- explanation is not highly convincing and the subject nesium and therapeutics. Magnes Res, 1994, 7, 313–328.
matter deserves further investigations. It would be ad- 10. Eby GA, Eby KL: Rapid recovery from major depression using magnesium treatment. Med Hypotheses, 2006, 67, visable to determine changes in magnesium level in urine and to check whether sildenafil is able to change 11. Eby GA, III, Eby KL: Magnesium for treatment-resistant magnesium concentration in mice chronically treated depression: a review and hypothesis. Med Hypotheses, with this bioelement.
2010, 74, 649–660.
In conclusion, our results indicate for the first time 12. Esplugues JV: NO as a signalling molecule in the nerv- ous system. Br J Pharmacol, 2002, 135, 1079–1095.
that sildenafil reverse the anti-immobility action of 13. Fawcett WJ, Haxby EJ, Male DA: Magnesium: physiol- magnesium in the forced swim test in mice and that ogy and pharmacology. Br J Anaesth, 1999, 83, 302–320.
simultaneous treatment with magnesium and silde- 14. Fox C, Ramsoomair D, Carter C: Magnesium: its proven nafil results in hypermagnesemia in laboratory ani- and potential clinical significance. South Med J, 2001, mals. Further studies are required to investigate the 94, 1195–1201.
15. Gee JB, Corbett RJ, Perlman JM, Laptook AR: Hypermag- mechanisms underlying the observed phenomena.
nesemia does not increase brain intracellular magnesium innewborn swine. Pediatr Neurol, 2001, 25, 304–308.
16. Ghofrani HA, Osterloh IH, Grimminger F: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov, 2006, 5, 689–702.
We gratefully acknowledge the technical assistance of Nina 17. Harkin A, Connor TJ, Burns MP, Kelly JP: Nitric oxide Kowalczyk. This study was supported by Funds for Statutory synthase inhibitors augment the effects of serotonin re- Activity of Maria Curie-Sk³odowska University, Lublin, Poland.
The authors wish to thank Polpharma S.A. (Starogard Gdañski, uptake inhibitors in the forced swimming test. Eur Neu- Poland) for generous gift of sildenafil.
ropsychopharmacol, 2004, 14, 274–281.
Pharmacological Reports, 2012, 64, 205–211 Sildenafil and antidepressant-like activity of magnesium
Katarzyna Soca³a et al.
18. Harkin AJ, Bruce KH, Craft B, Paul IA: Nitric oxide aminocyclopropanecarboxylic acid. J Pharmacol Exp synthase inhibitors have antidepressant-like properties Ther, 1993, 265, 1380–1386.
in mice. 1. Acute treatments are active in the forced 34. Padayatti PS, Pattanaik P, Ma X, van den Akker F: Struc- swim test. Eur J Pharmacol, 1999, 372, 207–213.
tural insights into the regulation and the activation 19. Hashimoto K: Emerging role of glutamate in the patho- mechanism of mammalian guanylyl cyclases. Pharmacol physiology of major depressive disorder. Brain Res Rev, Ther, 2004, 104, 83–99.
2009, 61, 105–123.
35. Poleszak E: Benzodiazepine/GABAA receptors are in- 20. Heiberg IL, Wegener G, Rosenberg R: Reduction of volved in magnesium-induced anxiolytic-like behavior cGMP and nitric oxide has antidepressant-like effects in in mice. Pharmacol Rep, 2008, 60, 483–489.
the forced swimming test in rats. Behav Brain Res, 2002, 36. Poleszak E: Modulation of antidepressant-like activity 134, 479–484.
of magnesium by serotonergic system. J Neural Transm, 21. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana 2007, 114, 1129–1134.
R, Kasper S: Treatment of severe mania with intravenous 37. Poleszak E, WlaŸ P, Kêdzierska E, Nieoczym D, Wróbel magnesium sulphate as a supplementary therapy. Psy- A, Fidecka S, Pilc A et al.: NMDA/glutamate mechanism chiatry Res, 1999, 89, 239–246.
of antidepressant-like action of magnesium in forced 22. Huang LJ, Yoon MH, Choi JI, Kim WM, Lee HG, swim test in mice. Pharmacol Biochem Behav, 2007, 88, Kim YO: Effect of sildenafil on neuropathic pain and hemodynamics in rats. Yonsei Med J, 2010, 51, 82–87.
38. Poleszak E, WlaŸ P, Kêdzierska E, Nieoczym D, Wyska 23. Ikari A, Nakajima K, Taki S, Suketa Y: Up-regulation of E, Szymura-Oleksiak J, Fidecka S et al.: Immobility Na+-dependent Mg2+ transport by nitric oxide and cyclic stress induces depression-like behavior in the forced GMP pathway in renal epithelial cells. Eur J Pharmacol, swim test in mice: effect of magnesium and imipramine.
2002, 451, 133–139.
Pharmacol Rep, 2006, 58, 746–752.
24. Imada Y, Yoshioka S, Ueda T, Katayama S, Kuno Y, 39. Poleszak E, WlaŸ P, Kêdzierska E, Radziwoñ-Zaleska M, Kawahara R: Relationships between serum magnesium Pilc A, Fidecka S, Nowak G: Effects of acute and levels and clinical background factors in patients with chronic treatment with magnesium in the forced swim mood disorders. Psychiatry Clin Neurosci, 2002, 56, test in rats. Pharmacol Rep, 2005, 57, 654–658.
40. Poleszak E, WlaŸ P, Szewczyk B, Kêdzierska E, Wyska 25. Kalivas PW, Duffy P, Eberhardt H: Modulation of A10 E, Librowski T, Szymura-Oleksiak J et al.: Enhancement dopamine neurons by gamma-aminobutyric acid ago- of antidepressant-like activity by joint administration of nists. J Pharmacol Exp Ther, 1990, 253, 858–866.
imipramine and magnesium in the forced swim test: Be- 26. Mohler H: GABA havioral and pharmacokinetic studies in mice. Pharmacol A receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J Recept Signal Biochem Behav, 2005, 81, 524–529.
Transduct Res, 2006, 26, 731–740.
Porsolt RD, Bertin A, Jalfre M: Behavioral despair inmice: a primary screening test for antidepressants. Arch 27. Mora F, Segovia G, Del Arco A: Glutamate-dopamine- Int Pharmacodyn Ther, 1977, 229, 327–336.
GABA interactions in the aging basal ganglia. Brain Res 42. Prast H, Philippu A: Nitric oxide as modulator of neu- Rev, 2008, 58, 340–353.
ronal function. Prog Neurobiol, 2001, 64, 51–68.
28. Mordes JP, Wacker WE: Excess magnesium. Pharmacol 43. Romani A: Regulation of magnesium homeostasis and Rev, 1977, 29, 273–300.
transport in mammalian cells. Arch Biochem Biophys, 29. Nieoczym D, £uszczki JJ, Czuczwar SJ, WlaŸ P: Effect 2007, 458, 90–102.
of sildenafil on the anticonvulsant action of classical and 44. Rosen RC, McKenna KE: PDE-5 inhibition and sexual second-generation antiepileptic drugs in maximal response: pharmacological mechanisms and clinical out- electroshock-induced seizures in mice. Epilepsia, 2010, comes. Annu Rev Sex Res, 2002, 13, 36–88.
51, 1552–1559.
45. Skolnick P, Popik P, Trullas R: Glutamate-based antide- 30. Nieoczym D, Soca³a K, Rundfeldt C, WlaŸ P: Effects of pressants: 20 years on. Trends Pharmacol Sci, 2009, 30, sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats. Pharmacol 46. Swaminathan R: Magnesium metabolism and its disor- Rep, 2010, 62, 383–391.
ders. Clin Biochem Rev, 2003, 24, 47–66.
31. Nieoczym D, Soca³a K, WlaŸ P: Lack of effect of silde- 47. Topf JM, Murray PT: Hypomagnesemia and hypermag- nafil on cocaine-induced convulsions in mice. Pharmacol nesemia. Rev Endocr Metab Disord, 2003, 4, 195–206.
Rep, 2009, 61, 930–934.
48. Uthayathas S, Karuppagounder SS, Thrash BM, 32. Nowak G, Legutko B, Skolnick P, Popik P: Adaptation Parameshwaran K, Suppiramaniam V, Dhanasekaran M: of cortical NMDA receptors by chronic treatment with Versatile effects of sildenafil: recent pharmacological ap- specific serotonin reuptake inhibitors. Eur J Pharmacol, plications. Pharmacol Rep, 2007, 59, 150–163.
1998, 342, 367–370.
33. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA: Adaptive changes in the N-methyl-D-aspartate receptorcomplex after chronic treatment with imipramine and 1- Received: July 6, 2011; accepted: September 1, 2011.
Pharmacological Reports, 2012, 64, 205–211

16 Review ΠChemical structure of phenothiazines and their biological activity.

Agata Jaszczyszyn, Kazimierz G¹siorowski, Piotr „wi¹tek, Wies³aw Malinka, Katarzyna Cieœlik-Boczula, Joanna Petrus, Bogus³awa Czarnik-Matusewicz

24 Review Œ What™s the role of topiramate in the management of patients with hyperkinetic movement disorders?

Antonio Siniscalchi, Luca Gallelli, Chiara Giofrè, Giovambattista De Sarro

31 Review ΠAnimal models of acute renal failure.

Amrit Pal Singh, Arunachalam Muthuraman, Amteshwar Singh Jaggi, Nirmal Singh, Kuldeep Grover, Ravi Dhawan

45 Anxiogenic effect of CCK8s in the ventral hippocampus of rats: possible involvement of GABAA receptors.

Akbar Hajizadeh Moghaddam, Robabeh Sadat Hosseini, Ali Roohbakhsh

54 Anxiolytic-like effect of losartan injected into amygdala of the acutely stressed rats.

Luis H. Llano López, Fernando Caif, Sebastián García, Miriam Fraile, Adriana I. Landa, Gustavo Baiardi, José V. Lafuente, Jan J. Braszko, Claudia Bregonzio, Pascual A. Gargiulo

64 Sub-chronic exposure to noise affects locomotor activity and produces anxiogenic and depressive like behavior in rats.

Fizza Naqvi, Saida Haider, Zehra Batool, Tahira Perveen, Darakhshan J. Haleem

70 Repeated administration of caffeine induces either sensitization or tolerance of locomotor stimulation depending on the environmental context.

Roberta Zancheta, Ana P.M. Possi, Cleopatra S. Planeta, Marcelo T. Marin

78 Chronic ethanol tolerance as a result of free-choice drinking in alcohol-preferring rats of the WHP line.

Wanda Dyr, Ewa Taracha

84 Analgesia and serum assays of controlled-release dihydrocodeine and metabolites in cancer patients with pain.

Wojciech Leppert, Przemys³aw Miko³ajczak, Ewa Kamiñska, Micha³ Szulc

94 Central effect of crocin on penicillin-induced epileptiform activity in rats.

Esmaeal Tamaddonfard, Nasrin Hamzeh Gooshchi, Sona Seiednejad-Yamchi

102 Analgesic and anticonvulsant activity of new derivatives of 2-substituted 4-hydroxybutanamides in mice.

Kinga Sa³at, Katarzyna Kulig, Robert Sa³at, Barbara Filipek, Barbara Malawska

113 Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery.

Pawe³ Wiczling, Agnieszka Bienert, Pawe³ Sobczyñski, Roma Hartmann-Sobczyñska, Krzysztof Bieda, Aleksandra Marcinkowska, Maria Malatyñska, Roman Kaliszan, Edmund Grzeœkowiak

123 Influence of 825 C>T polymorphism of G protein b3 subunit gene (GNB3) on hemodynamic response during dobutamine stress echocardiography. Anna Banaœ, Edyta P³oñska, Barbara Larysz, Mateusz Kurzawski, Marek Dro�dzik

129 Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes.

Rachel D. Wilson, Md. Shahidul Islam

140 Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.

Nirav Dhanesha, Amit Joharapurkar, Gaurang Shah, Vipin Dhote, Samadhan Kshirsagar, Rajesh Bahekar, Mukul Jain

150 Modulatory effect of insulin on T cell receptor mediated calcium signaling is blunted in long lasting type 1 diabetes mellitus.

Urszula Demkow, Pawe³ Winklewski, Olga Ciepiela, Katarzyna Popko, Anna Lipiñska, Anna Kucharska, Beata Michalska, Maria W¹sik

157 Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line.

Patrycja Kwieciñska, Erik Taubøll, Ewa £. Gregoraszczuk

166 Hematological effects of exposure to mixtures of selected ethylene glycol alkyl ethers in rats.

Beata Starek-„wiechowicz, Katarzyna Miranowicz- Dzier¿awska, Wies³aw Szymczak, Bogus³awa Budziszewska, Andrzej Starek

179 Modulation of Th1/Th2 cytokine production by selective and nonselective phosphodiesterase inhibitors administered to mice.

Marianna Szczypka, Sebastian Ploch, Bo¿ena Obmiñska-Mrukowicz

185 Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.

Andrzej Pawlik, Violetta Dziedziejko, Mateusz Kurzawski, Krzysztof Safranow, Daniel Kotrych, Andrzej Bohatyrewicz

191 Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental

Danish Mahmood, Razia Khanam, Krishna Kolappa Pillai, Mohd Akhtar

SHORT COMMUNICATIONS

205 Influence of the phosphodiesterase type 5 inhibitor, sildenafil, on antidepressant-like activity of magnesium in the forced swim test in mice.

Katarzyna Soca³a, Dorota Nieoczym, Ewa Poleszak, Piotr Wla�

212 Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients.

Kazuhiko Kotani, Toshiyuki Yamada, Michiaki Miyamoto, Shun Ishibashi, Nobuyuki Taniguchi, Alejandro Gugliucci

217 New conjugates of muramyl dipeptide and nor-muramyl dipeptide linked to tuftsin and retro-tuftsin derivatives significantly influence their biological activity.

Krystyna Dzierzbicka, Anna Wardowska, Ma³gorzata Rogalska, Piotr Trzonkowski

246 Note to Contributors

Source: http://rabbit.if-pan.krakow.pl/pjp/pdf/2012/1_205.pdf